AZD2932

SKU: orb1307352

Description

AZD2932 is a multi-targeted kinase inhibitor with potent activity against VEGFR2, PDGFβ, Flt-3, and c-Kit. It is a valuable research tool for studying angiogenesis and oncogenesis in both cellular and animal models of cancer and other proliferative diseases.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 883986-34-3
• MW: 447.49
• Purity: 97.71%
• Formula: C₂₄H₂₅N₅O₄
• SMILES: COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(c4)C(C)C)cc3)c2cc1OC
• Target: VEGFR,PDGFR,FLT,c-Kit
• Solubility: DMSO:82 mg/mL (183.24 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.47 mM);Ethanol:5 mg/mL (11.17 mM)

Bioactivity

• Target IC50:
  VEGFR2:8 nM|c-Kit:9 nM|FLT3:7 nM|PDGFRβ:4 nM
• In Vivo:
  AZD2932 effectively inhibits the phosphorylation of PDGFRα and PDGFRβ, demonstrating strong activity against a variety of receptors including VEGFR-2 (IC50=8 nM), PDGFRβ (IC50=4 nM), Flt-3 (IC50=7 nM), and c-Kit (IC50=9 nM).
• In Vitro:
  In the C6 rat glioma model, oral administration of AZD2932 (12.5 or 50 mg/kg, b.i.d.) was able to inhibit tumor growth. Additionally, in xenografts with tumors not expressing PDGFβ, oral doses of AZD2932 (50 mg/kg, b.i.d.) succeeded in suppressing the growth of Calu-6 and LoVo tumors.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cluster of differentiation antigen 135, CD135, CD117, c-Kit, cKit, AZD2932, AZD-2932, AZD 2932, Fms like tyrosine kinase 3, FLT3, inhibit, Inhibitor, PDGFRβ, PDGFR, Platelet-derived growth factor receptor, SCFR, VEGFR2, VEGFR, Vascular endothelial growth factor receptor

Compound Identifiers

PubChem CID

11517980